The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review


Synonyms: TAXOL,, Taxol?, GNF-Pf-2533, AGN-PC-000A63, CHEMBL601767, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of paclitaxel


Chemical compound and disease context of paclitaxel

  • Chest pain (grade 3), myalgia (grade 3), and fatigue (grade 3) were dose-limiting toxicities at dose level 4 (225 mg/m2 17-AAG and 80 mg/m2 paclitaxel) [10].

Associations of paclitaxel with other chemical compounds

  • On the other hand, mutation of Ala(115) to serine in beta4a-tubulin almost completely reversed heightened sensitivity to paclitaxel, but introduction of an S115A mutation into beta4b had no effect, suggesting that a complex interaction of multiple amino acids are necessary to produce this phenotype [11].
  • Median PFS in the polysomy group was 20.9 and 24.4 weeks for paclitaxel plus lapatinib and paclitaxel plus placebo, respectively [12].

Gene context of paclitaxel


  1. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. Hsueh, W.A., Kesner, A.L., Gangloff, A., Pegram, M.D., Beryt, M., Czernin, J., Phelps, M.E., Silverman, D.H. J. Nucl. Med. (2006) [Pubmed]
  2. Dominant negative Rac1 attenuates paclitaxel-induced apoptosis in human melanoma cells through upregulation of heat shock protein 27: a functional proteomic analysis. Lee, S.C., Sim, N., Clement, M.V., Yadav, S.K., Pervaiz, S. Proteomics (2007) [Pubmed]
  3. Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group. Joerger, M., Huitema, A.D., Richel, D.J., Dittrich, C., Pavlidis, N., Briasoulis, E., Vermorken, J.B., Strocchi, E., Martoni, A., Sorio, R., Sleeboom, H.P., Izquierdo, M.A., Jodrell, D.I., Calvert, H., Boddy, A.V., Hollema, H., Féty, R., Van der Vijgh, W.J., Hempel, G., Chatelut, E., Karlsson, M., Wilkins, J., Tranchand, B., Schrijvers, A.H., Twelves, C., Beijnen, J.H., Schellens, J.H. Clin. Cancer Res. (2007) [Pubmed]
  4. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Sui, M., Huang, Y., Park, B.H., Davidson, N.E., Fan, W. Cancer Res. (2007) [Pubmed]
  5. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Catalano, M.G., Poli, R., Pugliese, M., Fortunati, N., Boccuzzi, G. Endocr. Relat. Cancer (2007) [Pubmed]
  6. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Bauer, J.A., Chakravarthy, A.B., Rosenbluth, J.M., Mi, D., Seeley, E.H., De Matos Granja-Ingram, N., Olivares, M.G., Kelley, M.C., Mayer, I.A., Meszoely, I.M., Means-Powell, J.A., Johnson, K.N., Tsai, C.J., Ayers, G.D., Sanders, M.E., Schneider, R.J., Formenti, S.C., Caprioli, R.M., Pietenpol, J.A. Clin. Cancer Res. (2010) [Pubmed]
  7. Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies. Karapanagiotou, E.M., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, M.E., Larkin, J., Syrigos, K.N., Coffey, M., Thompson, B., Mettinger, K., Vile, R.G., Pandha, H.S., Hall, G.D., Melcher, A.A., Chester, J., Harrington, K.J. Clin. Cancer Res. (2012) [Pubmed]
  8. Regulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy. Leandro-García, L.J., Leskelä, S., Jara, C., Gréen, H., Avall-Lundqvist, E., Wheeler, H.E., Dolan, M.E., Inglada-Perez, L., Maliszewska, A., de Cubas, A.A., Comino-Méndez, I., Mancikova, V., Cascón, A., Robledo, M., Rodríguez-Antona, C. Clin. Cancer Res. (2012) [Pubmed]
  9. Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Wheeler, H.E., Gamazon, E.R., Wing, C., Njiaju, U.O., Njoku, C., Baldwin, R.M., Owzar, K., Jiang, C., Watson, D., Shterev, I., Kubo, M., Zembutsu, H., Winer, E.P., Hudis, C.A., Shulman, L.N., Nakamura, Y., Ratain, M.J., Kroetz, D.L., Cox, N.J., Dolan, M.E. Clin. Cancer Res. (2013) [Pubmed]
  10. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Ramalingam, S.S., Egorin, M.J., Ramanathan, R.K., Remick, S.C., Sikorski, R.P., Lagattuta, T.F., Chatta, G.S., Friedland, D.M., Stoller, R.G., Potter, D.M., Ivy, S.P., Belani, C.P. Clin. Cancer Res. (2008) [Pubmed]
  11. Heightened sensitivity to paclitaxel in Class IVa beta-tubulin-transfected cells is lost as expression increases. Yang, H., Cabral, F. J. Biol. Chem. (2007) [Pubmed]
  12. Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Downey, L., Livingston, R.B., Koehler, M., Arbushites, M., Williams, L., Santiago, A., Guzman, R., Villalobos, I., Di Leo, A., Press, M.F. Clin. Cancer Res. (2010) [Pubmed]
  13. Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment. Janssen, K., Pohlmann, S., Jänicke, R.U., Schulze-Osthoff, K., Fischer, U. Blood (2007) [Pubmed]
  14. The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Ahmed, A.A., Mills, A.D., Ibrahim, A.E., Temple, J., Blenkiron, C., Vias, M., Massie, C.E., Iyer, N.G., McGeoch, A., Crawford, R., Nicke, B., Downward, J., Swanton, C., Bell, S.D., Earl, H.M., Laskey, R.A., Caldas, C., Brenton, J.D. Cancer. Cell (2007) [Pubmed]
  15. Comparative proteomic analysis of paclitaxel sensitive A2780 epithelial ovarian cancer cell line and its resistant counterpart A2780TC1 by 2D-DIGE: the role of ERp57. Cicchillitti, L., Di Michele, M., Urbani, A., Ferlini, C., Donat, M.B., Scambia, G., Rotilio, D. J. Proteome Res. (2009) [Pubmed]
WikiGenes - Universities